From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.06
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

pigmentation (Kit) cell differentiation (Kit) extracellular space (Kit)
plasma membrane (Kit) nucleus (Kit) kinase activity (Kit)
Anatomy Link Frequency
platelet 2
stem cell 2
Kit (Mus musculus)
Pain Link Frequency Relevance Heat
aspirin 4 63.28 Quite High
fibrosis 3 48.20 Quite Low
Pain 5 32.40 Quite Low
backache 1 12.12 Low Low
Potency 5 5.00 Very Low Very Low Very Low
cva 4 5.00 Very Low Very Low Very Low
Paracetamol 4 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
Bioavailability 3 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 61 97.96 Very High Very High Very High
Myelofibrosis 29 96.80 Very High Very High Very High
Myeloid Leukemia 145 93.36 High High
Apoptosis 6 93.28 High High
Hyperplasia 2 92.24 High High
Splenic Rupture 1 89.08 High High
Systemic Mastocytosis 13 88.80 High High
Hypereosinophilic Syndrome 15 84.68 Quite High
Gastrointestinal Stromal Tumor 4 83.36 Quite High
Leukemia 34 77.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nilotinib was also as effective as imatinib in inhibiting phosphorylation of c-kit in HMC-1(560) cells.
Negative_regulation (inhibiting) of Phosphorylation (phosphorylation) of c-kit
1) Confidence 0.31 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 0.68 Pain Relevance 0
Based upon the potential for imatinib mesylate to inhibit the tyrosine kinase phosphorylation of c-Kit (the stem cell factor receptor essential for erythroid progenitor cell proliferation) imatinib mesylate was tested in a variety of trials for PV.
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of c-Kit in stem cell associated with myelodysplastic syndromes
2) Confidence 0.16 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 0.91 Pain Relevance 0.03
Imatinib is a 2-phenylaminopyrimidin derivate (Figure 1) and was initially developed as a specific platelet-derived growth factor receptor (PDGFR) inhibitor, but was later found to inhibit autophosphorylation of Abl and c-Kit.
Negative_regulation (inhibit) of Phosphorylation (autophosphorylation) of c-Kit in platelet
3) Confidence 0.07 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.46 Pain Relevance 0

General Comments

This test has worked.

Personal tools